Free Trial

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Raises Dividend to $0.17 Per Share

ProShares Ultra Nasdaq Biotechnology logo with background

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) declared a quarterly dividend on Tuesday, June 24th, NASDAQ Dividends reports. Stockholders of record on Wednesday, June 25th will be paid a dividend of 0.1706 per share by the exchange traded fund on Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date of this dividend is Wednesday, June 25th. This is a 30.3% increase from ProShares Ultra Nasdaq Biotechnology's previous quarterly dividend of $0.13.

ProShares Ultra Nasdaq Biotechnology Stock Down 0.5%

BIB traded down $0.24 during trading on Friday, reaching $45.79. The company had a trading volume of 4,002 shares, compared to its average volume of 11,301. The business has a 50 day simple moving average of $44.62 and a 200-day simple moving average of $49.03. The stock has a market cap of $50.37 million, a P/E ratio of 20.68 and a beta of 1.63. ProShares Ultra Nasdaq Biotechnology has a 52 week low of $33.78 and a 52 week high of $69.56.

ProShares Ultra Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Read More

Dividend History for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Should You Invest $1,000 in ProShares Ultra Nasdaq Biotechnology Right Now?

Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.

While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines